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ABSTRACT
Gastrointestinal cancer is one of the health problems which is frequently found in many people in the world 
until now. Studies in gastrointestinal cancer showed early detection can reduce morbidity and improve the 
survival of patients. The precancerous lesions of the gastrointestinal tract are highly potential turn into cancer. 
Precancerous lesions can be defined as a change or non-cancerous lesions that can become cancerous over time. 
Precancerous lesions can be found on the entire upper and lower gastrointestinal tract. Precancerous lesions of 
the upper digestive tract that can be found are Barrett's esophagus, chronic gastritis with or without Helicobacter 
pylori infection, atrophic gastritis, intestinal metaplasia of the gastric mucosa, epithelial dysplasia, and adenoma 
polyp. While precancerous lesions in the lower gastrointestinal tract are adenoma, inflammatory bowel disease, 
chronic infection and hereditary non-polyposis colon lesions. Precancerous lesions of the stomach in the form of 
chronic atrophic gastritis, intestinal metaplasia and dysplasia can be treated with anti-inflammatory and anti-
free radical drugs such as rebamipide and superoxide dysmutase. Precancerous lesions in the colon in the form 
of chronic enterocolitis, dysplasia can be treated with anti-oxidants, anti-inflammatory and anti-free radical 
such as anti-oxidants, rebamipide, superoxide dismutase, anti-inflammatory drugs.
Keywords: precancerous lesions, gastrointestinal tract, intestinal metaplasia, dysplasia.
ABSTRAK
Kanker gastrointestinal merupakan salah satu masalah kesehatan yang sering ditemukan di dunia sampai 
sekarang. Studi pada kanker gastrointestinal menunjukkan bahwa deteksi dini dapat mengurangi morbiditas 
dan meningkatkan kelangsungan hidup pasien. Lesi prakanker pada saluran gastrointestinal sangat berpotensi 
berubah menjadi kanker. Lesi prakanker dapat didefinisikan sebagai lesi non-kanker yang bisa berubah menjadi 
kanker seiring dengan berjalannya waktu. Lesi prakanker dapat ditemukan pada semua saluran gastrointestinal 
bagian atas dan bawah. Lesi prakanker saluran pencernaan bagian atas yang dapat ditemukan adalah Esofagus 
Barrett, gastritis kronis dengan atau tanpa infeksi Helicobacter pylori, gastritis atrofi, “intestinal metaplasia” 
mukosa lambung, displasia epitel, dan polip adenoma. Sementara lesi prakanker di saluran cerna bagian bawah 
adalah adenoma, penyakit radang usus besar, infeksi kronis dan lesi usus besar non-poliposis bawaan. Lesi 
prakanker pada lambung berupa gastritis atrofik kronis, metaplasia usus dan displasia dapat diobati dengan 
obat anti radikal bebas/ anti-inflamasi seperti rebamipide dan superoxide dysmutase. Lesi prakanker di usus 
besar dalam bentuk enterokolitis kronis, displasia dapat diobati dengan anti-oksidan, anti-inflamasi dan anti-
radikal bebas seperti anti oksidan, rebamipide, superoxide dismutase, obat anti-inflamasi.
Kata kunci: lesi prakanker, saluran gastrointestinal, metaplasia intestinal, displasia
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INTRODUCTION
Gastrointestinal cancer is one of the health problems 
which are frequently found in many people in the world 
until now. Gastrointestinal cancer mortality rate is still 
high enough, despite there are already advance medical 
technologies and good medications for gastrointestinal 
disease.1 From the studies in gastrointestinal cancer, 
early detection can reduce morbidity and improve the 
survival of patients.1
 Gastrointestinal cancers arise through a cascade of 
precursor that is already known about inflammatory 
– ranging from metaplasia-dysplasia-carcinoma 
sequence, so it is always via the stages of precancerous 
lesions.2 The precancerous lesions of the gastrointestinal 
tract are highly potential turn into cancer. The task is to 
find precancerous lesions of the gastrointestinal tract as 
early as possible, so that we can prevent the occurrence 
of cancer of the gastrointestinal tract.3 
DEFINITION OF PRECANCEROUS LESIONS
Precancerous lesions can be defined as a change or 
a non-cancerous lesions that can become cancerous 
over time.4 Precancerous lesion is a common condition 
associated with increased risk to turn into cancer. If left 
untreated the condition will turn into cancer.
TYPES AND CLASSIFICATION OF PRECANCEROUS 
LESIONS
Precancerous lesions can be found on the entire 
upper and lower gastrointestinal tract. Precancerous 
lesions of the upper digestive tract that can be found are 
Barrett's esophagus, chronic gastritis with or without 
Helicobacter pylori infection, atrophic gastritis, 
intestinal metaplasia of the gastric mucosa, epithelial 
dysplasia, and adenoma polyp.2,3,5,6 
While gastrointestinal precancerous lesions that can 
be found in the lower gastrointestinal tract are adenoma 
(tubular, tubulovillous and villous), inflammatory 
bowel disease (including Crohn's disease and ulcerative 
colitis), chronic infection and hereditary non-polyposis 
colon lesions.3,6 
Chronic atrophic gastritis should be diagnosed 
and graded on the basis of the presence of chronic 
inflammatory cells, including lymphocytes and 
plasma cells that expand the lamina propria, and the 
disappearance of the normal glands.7-9 In the gastric 
body/fundus this is associated with a loss of specialized 
cells and thus a reduction of gastric secretory functions. 
The severity of gland loss (atrophy) should be graded 
although inter- and intraobserver agreement are both 
poor.
EPIDEMIOLOGY
Studies in the world revealed that the annual 
incidence of gastric cancer from atrophic gastritis, 
intestinal metaplasia and dysplasia, ranging from 0-2%, 
0-10% and 0-73%.10 A study from the Netherland found 
that the annual incidence of gastric cancer is 0.1% for 
patients with atrophic gastritis, 0.25% for intestinal 
metaplasia, 0.6% for mild-to-moderate dysplasia 
and 6% for severe dysplasia within 5 years after 
diagnosis.1 Risk factors for gastric cancer increased 
the severity of gastric premalignant lesions at the time 
of initial diagnosis, for example, severe dysplasia 
(HR = 40.14, 95%), Increased age (75-84 years, 
HR = 3.75, 95%), and male gender (HR = 1.50). The 
authors concluded from this study that patients with 
premalignant gastric lesions are at increased risk of 
gastric cancer.1
A population study in Shandong province of 
China with gastroscopy examination found that the 
prevalence of chronic atrophic gastritis 98%, gastric 
intestinal metaplasia obtained 33%, 20% gastric 
dysplasia. Found no sex differences in the prevalence 
of chronic atrophic gastritis. The prevalence of 
intestinal metaplasia and dysplasia lesions increased 
significantly corresponding increase in age.11
Colorectal adenomatous polyp has chance to 
develop into carcinoma about 0.25% per year; the 
transformation rate is proportional with the size of 
adenoma. Adenomas with size less than 1 cm had 
much lower chance to transform into carcinoma 
compared with adenomas sized > 2 cm (1% vs. 50%). 
The tubulovillous and villous adenoma polyp had 50% 
chance for developing colorectal cancer. The colorectal 
adenoma can be found as incidental findings during 
colonoscopy screening in 40% of people older than 60 
years old.12 Study from Korea showed that patients with 
ulcerative colitis had cumulative risk of developing 
colorectal cancer for 0.7% at 10 years, 7.9% at 20 
years, and 33.2% at 30 years.13 Meta-analysis showed 
that the cumulative risk of developing colorectal cancer 
following diagnosis of Chron’s disease is 2.9%.14
PATHOGENESIS
The changes from normal lesions become 
precancerous lesions and then into gastrointestinal 
cancers triggered by many factors such as. genetics, 
infection (e.g. Helicobacter pylori infection in gaster, 
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intestinal tuberculosis infection, etc.), inflammation(e.g. 
Crohn's disease, ulcerative colitis), diet, stress (anxiety, 
depression), and oxidative stress or free radicals.15-17 
Chronic inflammation cells will produce 
microenvironment that may promote the cancer 
development and progression.18 Prolonged and 
overproduction of cytokines e.g. Tumor Necrosis 
Factor (TNF-α), interleukin-6 (IL-6) may induce the 
production of free radical agents such as reactive 
oxygen and nitrogen species (ROS and NOS). ROS 
and NOS will induce DNA damage, genomic instability 
and alter the transcription factors (nuclear factor-kB), 
signaling proteins, carcinogenesis factors (p53, DNA 
Mismatch Repair proteins).12,18-20 Proinflammatory 
cytokines may act as tumor growth factor, therefore 
may induce proliferation of tumor cells. Chronic 
inflammation also can induce epithelial mesenchymal 
transition, angiogenesis, and metastasis.18 
SUPPORTING EXAMINATION
Supporting examinations used for diagnosis or 
screening and follow-up of precancerous lesions of 
the gastrointestinal tract are endoscopy, histopathology 
examination, examination miRNA.3,9,21 Gastrointestinal 
endoscopy must be done regularly and consists of 
esophagogastroduodenoscopy, colonoscopy and 
enteroscopy with Chromo-endoscopy staining 
(blue methylen, indigocarmine, Lugol) or Narrow 
band imaging technique (NBI) or endo-microscopy 
examinations. Histopathology examination is an 
important examination that should be performed 
to diagnose the presence of precancerous lesions. 
Histopathology examination of mucosal biopsies 
obtained through the digestive tract. Histopathology 
examination was performed with specific staining such 
as Haematoxylin-eosin (to detect intestinal metaplasia, 
dysplasia), PAS and HID Alcian blue Alcian blue 
(to detect subtypes of intestinal metaplasia) or other 
staining.9 Examination of endo-microscopy performed 
using confocal laser endomicroscope Pentax or with 
Cellvizio probe-based optical mini microscope.22-25 
MiRNA expression can differentiate normal to 
pathological lesions, and among precancerous lesions, 
it may be able to classify different subtypes.3 
MANAGEMENT
The diagnosis of precancerous lesions of the GI tract 
is done by history taking of the patients complaints & 
clinical manifestations, family history of GI tract cancer, 
physical examination and supporting examinations.26 
Supporting examinations which is necessary include 
blood hemoglobin level, erythrocyte sedimentation rate 
(ESR), C reactive protein (CRP), stool examination 
i.e. Fecal occult blood (stool occult blood test), fecal 
calprotectin and fecal M2 Pyruvate Kinase (M2PK).26-
28 Examination with high sensitivity and specificity 
close to 100% to diagnose precancerous lesion/
cancer are esophagogastroduodenoscopy examination, 
colonoscopy, enteroscopy, Chromo-endoscopy and 
confocal laser endomicroscopy with biopsy examination 
and histopathology examination.21,29 These supporting 
examinations must be performed periodically to monitor 
the progress of precancerous lesions. 
European Society of Gastroenterology (ESGE), 
EHSG, ESP and SPED proposed the management 
of precancerous conditions and lesions in the 
stomach.2 Conventional white light endoscopy can 
not accurately differentiate between and diagnose pre-
neoplastic gastric conditions/lesions. Magnification 
chromoendoscopy or narrow-band imaging (NBI) 
endoscopy with or without magnification may be 
offered in these cases as it improves diagnosis of such 
lesions. At least four biopsies of the proximal and 
distal stomach, on the lesser and greater curvature, 
are needed for adequate assessment of premalignant 
gastric conditions.2 Systems for histopathological 
staging (e.g. operative link for gastritis assessment 
and operative link for gastric intestinal metaplasia 
assessment) may be useful for identifying subgroups 
of patients with different risks of progression to 
gastric cancer, namely those with extensive lesions 
(i.e., atrophy and/or intestinal metaplasia in both 
antrum and corpus). Low serum pepsinogen levels 
can also predict this phenotype and, in such patients, 
Helicobacter pylori serology may be useful for further 
detection of high risk individuals. Family history of 
gastric cancer, neither age, gender, H. pylori virulence 
factors, or host genetic variations change these clinical 
recommendations.2 Patients with extensive atrophy 
and/or extensive intestinal metaplasia should be offered 
endoscopic surveillance every 3 years. Patients with 
mild to moderate atrophy/intestinal metaplasia only in 
antrum do not need follow-up. If Helicobacter pylori 
infection is present, eradication should be offered to 
prevent high grade dysplasia or carcinoma. Currently, 
the use of cyclooxygenase-2 (COX-2) inhibitors or 
the use of dietary supplementation with antioxidants 
(ascorbic acid and beta-carotene) are not endorsed 
as approaches to decrease the risk of progression of 
gastric precancerous lesions. Patients with dysplasia 
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without a visible endoscopic lesion should be closely 
followed up, either immediately and 6 to 12 months 
thereafter, or within 12 months, for those with high 
grade or low grade dysplasia. Those with dysplasia or 
cancer within an endoscopically visible lesion should 
undergo staging and resection.2
Precancerous lesions of the stomach in the form 
of chronic atrophic gastritis, intestinal metaplasia and 
dysplasia can be treated with anti-inflammatory and anti-
free radical drugs such as rebamipide and superoxide 
dysmutase (SOD).30-32 Chronic gastritis caused by 
Helicobacter pylori infection must get an eradication 
therapy for H. pylori.33 The principle of eradication 
therapy for Helicobacter pylori divided into triple and 
quadruple therapy. Triple therapy consisted of proton 
pump inhibitor and 2 antibiotics. Quadruple therapy 
consisted of bismuth agent (bismuth subcitrate etc), 
proton pump inhibitor and 2 antibiotics. The proton pump 
inhitors which can used are omeprazole, lansoprazole, 
rabeprazole, pantoprazole, esomeprazole, tenatoprazole. 
Antibiotics that can eradicate Helicobacter pylori 
infection are amoxicillin, clarithromycin, metronidazole, 
azithromycin, tetracycline, and levofloxacin.33,34 
Precancerous lesions in the colon in the form of chronic 
enterocolitis, dysplasia can be treated with anti-oxidants, 
anti-inflammatory and anti-free radical al anti-oxidants 
(vitamin A, vitamin C, vitamin E, polyphenols 
and astaxantin), rebamipide, superoxide dismutase 
(SOD), anti-inflammatory drugs (sulfasalazine, 
mesalamine/5-ASA, corticosteroid), aspirin).30-32,35-42 
Chronic infections in the intestine must be treated 
with antibiotics according to the cause of infection. 
If the cause is tuberculosis infection, the patient 
must be treated with anti tuberculosis drugs for 9-12 
months. The anti tuberculosis drugs are isoniazid, 
rifampicine, ethambuthol, pirazinamide, etc.43,44 
Adenoma polyp in the gaster, small intestine and colon 
must be removed by endoscopic polypectomy as soon 
as possible.45,46 
ALGORITHM OF MANAGEMENT OF PRECANCEROUS 
LESIONS OF THE GI TRACT
 European Society of Gastroenterology(ESGE), 
EHSG, ESP and SPED proposed an algorithm 
(flowchart) for the management of precancerous 
lesions of the gaster.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Several biopsies should be obtained 
(≥2 in antrum and ≥2 in 
corpus;lesser and greater curvature) 
Spread of lesion Grade of dysplasia 
Mild/moderat
e atrophic 
gastritis or 
intestinal 
metaplasia 
only in 
antrum 
Atrophic 
gastritis or 
intestinal 
metaplasia 
both in antrum 
and corpus 
Low grade High grade 
H.pylori eradication 
Follow-up Staging 
& 
Immediately and 6-12 
months 
<12 months 
Patients with atrophic gastritis 
and/or intestinal metaplasia without 
dysplasia 
Patients with dysplasia 
Extension Visible endoscopic lesion? 
Magnification chromoendoscopy and/or narrow band imaging (NBI) may be offered 
Every 3 years 
Figure 1. Algorithm (flowchart) for the management of precancerous lesions of the 
gaster[cited from 2]
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World Gastroenterology Organization recommends 
guidelines for colon cancer and precancerous colon 
lesions, namely: (1) screening test with a stool test, the 
fecal occult blood test and fecal DNA; (2) screening test 
with endoscopy/colonoscopy and CT colonography.47
CONCLUSION
Precancerous lesions of the gastrointestinal tract are 
lesions that can turn into cancer. Detection, diagnosis, 
and treatment of precancerous lesions have to be 
done as early as possible so that we can prevent the 
occurrence of gastric cancer. 
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